

# Tivozanib

Catalog	No:	tcsc0	103
---------	-----	-------	-----

Available Sizes

size: 5mg

size: 10mg

size: 50mg

size: 100mg

size: 200mg

jize: 200mg

**CAS No:** 475108-18-0

Formula:

 $C_{22}H_{19}CIN_4O_5$ 

**Pathway:** Protein Tyrosine Kinase/RTK

### Target: VEGFR

## Purity / Grade:

>98%

Solubility:

DMSO : 25 mg/mL (54.96 mM; Need ultrasonic)

#### **Alternative Names:**

AV-951;KRN951

Copyright 2021 Taiclone Biotech Corp.



**Observed Molecular Weight:** 

454.86


# **Product Description**

Tivozanib (AV-951; KRN951) is a highly potent and selective **VEGFR 1/2/3** inhibitor with **IC<sub>50</sub>**s of 0.21, 0.16, and 0.24 nM in cell assay, respectively.

IC50 & Target: IC50: 0.21 nM (VEGFR 1), 0.16 nM (VEGFR 2), 0.24 nM (VEGFR 3)<sup>[1]</sup>

In Vitro: Tivozanib potently inhibits VEGF-induced VEGFR2 phosphorylation in endothelial cells ( $IC_{50}=0.16$  nM). It also inhibits ligandinduced phosphorylation of PDGFR $\beta$  and c-Kit ( $IC_{50}=1.72$  and 1.63 nM, respectively). Tivozanib blocks VEGF-dependent, but not VEGF-independent, activation of mitogenactivated protein kinases and proliferation of endothelial cells. It inhibits VEGF-mediated migration of human umbilical vein endothelial cells<sup>[1]</sup>.

*In Vivo:* Following p.o. administration to athymic rats, Tivozanib decreases the microvessel density within tumor xenografts and attenuates VEGFR-2 phosphorylation levels in tumor endothelium. It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.